Poseida Therapeutics, INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
10-Q: Poseida Therapeutics Reports Positive Cash Flow in Q3 2024 Amidst Strong Collaboration Revenue
Poseida Therapeutics reports a net loss of $35.4 million for the nine months ended September 30, 2024, but positive cash flow from operations of $13.7 million, driven by significant collaboration revenue.
Poseida Therapeutics reports a net loss of $55.6 million for the first half of 2024, but also positive cash flow from operations of $23.3 million, and highlights progress in its allogeneic CAR-T and genetic medicines programs.
10-Q: Poseida Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
Poseida Therapeutics reports increased collaboration revenue and provides updates on its clinical programs in its first quarter 2024 financial results.